---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-006509"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T16:46:51.603269+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oncotelic CMO Fatih Uckun resigns; CRO Seymour Fein assumes CMO role

## Summary
- Fatih Uckun, MD, PhD, resigned as Chief Medical Officer effective February 28, 2023.
- Seymour Fein, MD, currently Chief Regulatory Officer, will take over as CMO.
- Fein will continue as CRO while assuming additional CMO responsibilities.

## SEC filing metadata
- accession: 0001493152-23-006509
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315223006509/0001493152-23-006509-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315223006509/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-006509
- JSON: https://secwatch.observer/filing/0001493152-23-006509.json
- Plain text: https://secwatch.observer/filing/0001493152-23-006509.txt

## Key facts
- Executive change
  Fatih Uckun resigned as Chief Medical Officer at Oncotelic Therapeutics, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: On February 28, 2023, Fatih Uckun, MD, Ph. D, Chief Medical Officer (“ CMO ”) of Oncotelic Therapeutics, Inc. (the “ Company ”), notified the Company of his resignation as the Company’s CMO, effective February 28, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/908259/000149315223006509/0001493152-23-006509-index.htm
- Executive change
  Seymour Fein was appointed as Chief Medical Officer at Oncotelic Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Medical Officer
  source text: Dr. Seymour Fein MD, Chief Regulatory Officer (“CRO”) of the Company, will be taking over the CMO role.
  evidence_url: https://www.sec.gov/Archives/edgar/data/908259/000149315223006509/0001493152-23-006509-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.